The effect of SARS-CoV-2 mRNA vaccination on AMH concentrations in infertile women

doi:10.1016/j.rbmo.2022.06.015

Reproductive BioMedicine Online

Volume 45, Issue 4, October 2022, Pages 779-784

https://doi.org/10.1016/j.rbmo.2022.06.015 Get rights and content

ABSTRACT

Research question

Does SARS-CoV-2 mRNA vaccination affect the ovarian reserve of infertile women undergoing IVF?

Design

This was a prospective observational study at a single university-affiliated IVF unit that included infertile women aged 18–44 years who were undergoing IVF/intracytoplasmic sperm injection between November 2020 and September 2021, had received two doses of SARS-CoV-2 mRNA vaccination and had undergone measurement of baseline anti-Müllerian hormone (AMH) concentration within the 12 months preceding their recruitment. AMH concentrations before and after vaccination were evaluated and compared.

Results

Overall, 31 women were included in the study. The median AMH concentrations before and after COVID-19 vaccine were comparable (1.7 versus 1.6 g/ml, respectively, P = 0.96). No correlation was found between the participant's anti-COVID-19 antibody titre and the change in AMH concentration.

Conclusions

SARS-CoV-2 mRNA vaccination does not adversely affect ovarian reserve, as shown by comparing serum AMH concentrations before and after vaccination. These findings may serve as a counselling tool for clinicians to reassure women undergoing fertility treatment that SARS-CoV-2 mRNA vaccination is safe.

Keywords

Anti-Müllerian hormone

COVID-19

Fertility

Ovarian reserve

SARS-CoV-2 mRNA vaccine

Cited by (0)

Since 2007 Eran Horowitz has worked as a senior physician at the IVF unit, Department of Obstetrics and Gynecology, Wolfson Medical Center, Holon, and Sackler Faculty of Medicine, Tel Aviv University, Israel, where he currently holds the position of Senior Lecturer. He has published more than 40 scientific papers and book chapters.

Key message

In this study COVID-19 vaccination was not associated with a short-term reduction of ovarian reserve in women undergoing IVF, and anti-Müllerian hormone concentrations were similar before and after vaccination. These findings may serve as a counselling tool for clinicians to reassure women undergoing fertility treatment that SARS-CoV-2 mRNA vaccination is safe.

: Declaration: The authors report no financial or commercial conflicts of interest.

View Abstract